Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 21Recruiting 5Terminated 4Unknown 3Not yet recruiting 3Withdrawn 2Active not recruiting 2

Sponsor Class

OTHER 11INDUSTRY 3UNKNOWN 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Injections 39Carboplatin 33Capecitabine 24Paclitaxel 23Cisplatin 23Docetaxel 22pembrolizumab 21Oxaliplatin 21Gemcitabine 21Bevacizumab 19Pemetrexed 18Fluorouracil 13Irinotecan 12Cyclophosphamide 11osimertinib 9Nivolumab 9Dexamethasone 8Topotecan 7Leucovorin 7130-nm albumin-bound paclitaxel 7venetoclax 6toripalimab 6tislelizumab 6regorafenib 6lenvatinib 6fludarabine 6Doxorubicin 6Cetuximab 6daratumumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × Epirubicin × Clear all
NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06699576 2024-11-21

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

Hansoh BioMedical R&D Company

Phase 1 Not yet recruiting
448 enrolled
Sarcoma

Sarcoma, Osteosarcoma

NCT04301739 2020-03-12

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Shanghai Henlius Biotech

Phase 3 Not yet recruiting
522 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡